KPV vs PDA
Both KPV and PDA are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
KPV
Evidence C+α-MSH Tripeptide KPV
The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
View full KPV profile →PDA
Evidence C+Pentadeca Arginate (PDA)
A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.
View full PDA profile →Side-by-Side
| Attribute | KPV | PDA |
|---|---|---|
| Evidence Grade | C+ | C+ |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — newer compounded analog of BPC-157 |
| Typical Dose | 200–500 mcg orally or topical (research only) | 200–500 mcg daily (subcutaneous) |
| Clinics Indexed | 26 | 41 |
| Categories | anti-inflammatory, gut-health, skin | recovery, anti-inflammatory |
Key reported benefits — KPV
- ✓GI inflammation reduction
- ✓Skin inflammation reduction
- ✓Antimicrobial activity
Key reported benefits — PDA
- ✓Tissue repair
- ✓Anti-inflammation
- ✓Potentially better stability than BPC-157
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.